U.S. Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
224.81+4.50 (+2.04%)
At close: 1:00PM EST

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
http://www.amgen.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees23,400

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert A. BradwayChairman, CEO & Pres5.61MN/A1963
Mr. Jonathan P. GrahamExec. VP, Gen. Counsel & Sec.2.44MN/A1961
Dr. David M. Reese M.D.Exec. VP of R&D2.54MN/A1963
Mr. Murdo GordonExec. VP of Global Commercial Operations2.66MN/A1967
Mr. Peter H. GriffithExec. VP & CFON/AN/A1959
Mr. Esteban SantosExec. VP of OperationsN/AN/A1968
Ms. Linda H. LouieVP of Fin. & Chief Accounting OfficerN/AN/AN/A
Mr. Mike ZahigianSr. VP & Chief Information OfficerN/AN/AN/A
Mr. Arvind SoodVP of Investor RelationsN/AN/AN/A
Nancy A. GrygielSr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Corporate Governance

Amgen Inc.’s ISS Governance QualityScore as of November 1, 2019 is 2. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.